|Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Pyrroloquinoline quinone 是氧化还原辅助因子,一种阴离子型氧化还原循环原醌。它是哺乳动物的必需营养素,对免疫功能很重要。它是从嗜甲基细菌的培养物中分离的,也存在于哺乳动物的组织。
产品描述 | Pyrroloquinoline quinone (PQQ), as a well-known redox enzyme cofactor, PQQ can protect NS/PCs against glutamate toxicity associated with ROS-mediated mitochondrial pathway, |
体外活性 | Pyrroloquinoline quinone(PQQ)预处理显示了其在保护NS/PCs免受谷氨酸诱导的凋亡/坏死中的显著效果。PQQ的神经保护作用与细胞内活性氧(ROS)产生的减少、谷胱甘肽(GSH)水平的增加以及caspase-3活性的降低有关。此外,PQQ预处理还显著提高了暴露于谷氨酸的NS/PCs中超氧化物歧化酶(SOD)、过氧化氢酶(CAT)和谷胱甘肽过氧化物酶(GPx)的活性[1]。 |
体内活性 | Pyrroloquinoline quinone(PQQ),一种存在于多种人类食物中的天然抗氧化剂,在Balb/C小鼠的肝纤维化模型中显示出强大的抗纤维化和清除ROS活性。PQQ的抗氧化作用通过调节肝脏纤维化过程中多个步骤发挥作用,包括慢性肝损伤、肝脏炎症、肝星状细胞的激活以及细胞外基质的产生。PQQ还能在体内外抑制活化的HSCs中RACK1的上调。PQQ对于抑制小鼠的氧化应激和肝脏纤维化具有显著效果[2]。 |
动物实验 | Healthy male Balb/C mice of 4–6 week were used to induce liver fibrosis and isolate primary HSCs.?The animals were obtained from SLAC Laboratory Animal Corp in SPF microbiological status.?All mice were maintained at 25°C with a 12 h dark/light cycle and completely randomly grouped.?For thioacetamide (TAA)-induced liver fibrosis, which has been shown to be closely resemble the panlobular and parenchymal fibrosis that is found in most human chronic liver disease , TAA was given by intraperitoneal injection ?at 200 mg/kg body weight 3 times each week for 8 weeks.?For bile duct ligation (BDL)-induced liver fibrosis, BDL was performed according to previous report , and mice were sacrificed 2 weeks later.?Administration of PQQ started on the second day when TAA was firstly given or BDL was performed, and PQQ was given at the dose of 0.3 mg/kg or 1 mg/kg by gastrogavage administration daily before mice were sacrificed.?Silymarin (150 mg/kg) was used as the positive control by gastrogavage administration daily.?Total number of 405 mice were used.?Mice were sacrificed by cervical dislocation under anesthesia[2]. |
分子量 | 330.21 |
分子式 | C14H6N2O8 |
CAS No. | 72909-34-3 |
|Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 5 mg/mL (15.14 mM), Sonication is recommended.
H2O: 0.2 mg/mL (0.61 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.0284 mL | 15.1419 mL | 30.2838 mL | 75.7094 mL |
5 mM | 0.6057 mL | 3.0284 mL | 6.0568 mL | 15.1419 mL | |
10 mM | 0.3028 mL | 1.5142 mL | 3.0284 mL | 7.5709 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Pyrroloquinoline quinone 72909-34-3 Metabolism Others Endogenous Metabolite essential redox anionic inhibit Methoxatin co-factor PQQ bacteria function methylotropic immune nutrient Inhibitor inhibitor